论文部分内容阅读
目的研究全反式维甲酸（ＡＴＲＡ）和三氧化二砷（ＡＳ２Ｏ３）治疗急性早幼粒细胞白血病（ＡＰＬ）的长期疗效和预后相关因素。方法回顾性总结７２例经ＡＴＲＡ诱导缓解的初治ＡＰＬ患者长期无复发生存和总生存情况，并采用单因素分析对预后因素进行研究。结果７２例患者的３年和５年无复发生存率（ＲＦＳ）和总生存率（ＯＳ）分别为：３２．５％、１８．４％和７３．８％、５８．５％。初发病例在诱导缓解和缓解后治疗中，联合应用ＡＴＲＡ和化疗以及发病时ＷＢＣ计数与预后相关。ＡＳ２Ｏ３治疗复发ＡＰＬ，完全缓解和生存均高于常规化疗十维甲酸组。结论ＡＴＲＡ可作为初发病例的标准诱导治疗；缓解后联合应用化疗和ＡＴＲＡ能延缓或降低复发；在复发病例中，Ａｓ2Ｏ３治疗是首选方案。
Objective To investigate the long-term efficacy and prognostic factors of all-trans retinoic acid (ATRA) and arsenic trioxide (AS2O3) in the treatment of acute promyelocytic leukemia (APL). Methods We retrospectively reviewed the long-term recurrence-free survival and overall survival of 72 patients with APL-induced remission of APL. Univariate analysis was used to investigate the prognostic factors. Results The 3-year and 5-year recurrence-free survival (RFS) and overall survival (OS) of 72 patients were 32.5%, 18.4%, 73.8%, and 58.5%, respectively. Early-onset cases In the induction of remission and post-remission therapy, combined use of ATRA and chemotherapy and WBC counts at the time of onset correlate with prognosis. AS2O3 treatment of recurrent APL, complete remission and survival were higher than the conventional chemotherapy in the retinoid group. Conclusions ATRA can be used as a standard induction therapy for initial cases. Combination of chemotherapy and ATRA can delay or reduce recurrence after remission. As2O3 is the first choice for recurrence.